Skip to main content
    X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.83
    -0.29 (-9.29%)

    Market Cap: $318.59M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    X4 Pharmaceuticals Inc (XFOR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    X4 Pharmaceuticals reported revenue of $35.11M for the fiscal year ended Dec 31, 2025, up 1273.2% from the year before. That year, net income was -$79.20M with a net margin of -225.6%, operating cash flow was -$85.62M and free cash flow was -$85.62M. The quarter ended Sep 30, 2026 had revenue of $2.88M and net income of -$20.20M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $183.00K, a compound annual rate of 140.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$35.11M+1273.2%83.6%-247.4%-225.6%
    Dec 2024$2.56MN/A68.8%-1423.6%-1464.6%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021-$366.00K-114.3%N/AN/AN/A
    Dec 2020$2.56M+1300.5%100.0%-2336.1%-2424.2%
    Dec 2019$183.00KN/A100.0%-28253.0%-28856.3%
    Dec 2018-$89.00KN/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$35.11M$2.56M$0$0-$366.00K$2.56M$183.00K-$89.00K$0$0
    Cost of revenue$5.76M$797.00K$0$0$0$0$0$0$0$0
    Gross profit$29.36M$1.76M$0$0-$366.00K$2.56M$183.00K-$89.00K$0$0
    Research and development$72.72M$81.64M$72.02M$61.06M$50.65M$41.93M$30.16M$20.35M$28.13M$17.83M
    Operating income-$86.88M-$36.40M-$107.52M-$87.57M-$85.11M-$59.87M-$51.70M-$29.09M-$36.13M-$24.35M
    Net income-$79.20M-$37.45M-$101.17M-$93.87M-$88.70M-$62.13M-$52.81M-$33.28M-$33.88M-$22.98M
    EBITDA-$73.58M-$33.34M-$99.47MN/A-$84.18M-$58.62M-$51.37MN/A-$32.12M-$21.53M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.88M$8.81M$2.71M$2.14M$1.76M$1.97M$28.81M$1.43M$560.00K$563.00K$0$3.06M
    Gross profit$2.37M$7.19M$2.11M$1.78M$1.41M$1.65M$24.09M$1.13M$333.00K$295.00K$0-$62.00K
    Operating income-$19.99M-$16.39M-$20.31M-$23.70M-$27.51M-$26.23M-$9.44M-$35.72M-$34.50M$71.10M-$37.29M-$25.20M
    Net income-$20.20M-$16.16M-$20.24M-$23.93M-$29.82M-$25.74M$282.00K-$39.82M-$36.70M$90.83M-$51.77M-$19.13M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $77.28M by $139.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$290.46M$146.45M$147.26M$155.59M$117.18M$122.87M$160.70M$36.00M$81.25M$7.60M
    Current assets$261.58M$112.17M$122.08M$128.68M$87.88M$83.31M$129.28M$35.08M$79.53M$5.72M
    Cash and equivalents$217.05M$55.70M$99.22M$121.72M$81.79M$78.71M$126.18M$30.75M$76.79M$3.04M
    Total liabilities$104.17M$124.30M$96.16M$81.53M$52.76M$50.07M$31.48M$14.40M$22.55M$24.33M
    Short-term debt$994.00K$1.25M$1.10M$1.31M$795.00K$0$898.00K$1.69M$2.31M$5.13M
    Long-term debt$76.29M$75.42M$54.57M$32.30M$33.14M$33.18M$20.10M$7.89M$9.92M$10.13M
    Shareholder equity$186.29M$22.15M$51.10M$74.05M$64.41M$72.80M$129.22M$21.60M$58.71M-$16.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$231.82M$253.06M$270.28M$290.46M$163.56M$105.17M$130.01M$146.45M$178.16M$210.61M$112.18M$147.26M
    Total liabilities$92.93M$97.61M$101.83M$104.17M$101.94M$101.20M$107.07M$124.30M$118.54M$116.16M$111.15M$96.16M
    Cash and equivalents$185.80M$195.09M$216.91M$217.05M$69.63M$39.22M$40.26M$55.70M$97.41M$147.22M$60.49M$99.47M
    Shareholder equity$138.88M$155.45M$168.45M$186.29M$61.62M$3.97M$22.94M$22.15M$59.62M$94.45M$1.04M$51.10M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$85.62M-$130.90M-$96.51M-$77.10M-$70.91M-$58.82M-$48.05M-$25.42M-$27.87M-$21.64M
    Capital expenditures$0$326.00K$60.00K$103.00K$615.00K$1.36M$174.00K$0$42.00K$73.00K
    Free cash flow-$85.62M-$131.23M-$96.57M-$77.20M-$71.52M-$60.18M-$48.23M-$25.42M-$27.91M-$21.71M
    Dividends paidN/AN/AN/A$12$13.94M$12.39M$19.95MN/A$45.68MN/A
    Share repurchasesN/AN/AN/AN/A$2.00M$0$0N/A$0$0
    Investing cash flow$8.15M$66.99M-$14.88M-$103.00K-$615.00K-$1.36M$27.23M$0-$42.00K-$73.00K
    Financing cash flow$238.63M$20.29M$88.52M$117.23M$74.25M$12.39M$140.66M$6.87M$109.14M$18.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$20.19M-$20.79M-$19.60M-$15.53M-$27.82M-$29.90M-$12.37M-$32.99M-$34.03M-$30.28M-$33.60M-$27.75M
    Capital expendituresN/AN/A$19.60M$3.00M$3.00M$0$3.00M$41.00K$92.00K$134.00K$59.00K$35.00K
    Free cash flowN/AN/A-$39.20M-$18.53M-$30.82M-$29.90M-$15.37M-$33.04M-$34.12M-$30.41M-$33.66M-$27.78M
    Last 12 quarters

    Frequently Asked Questions About XFOR

    What is X4 Pharmaceuticals' annual revenue?

    X4 Pharmaceuticals reported revenue of $35.11M for the fiscal year ended Dec 31, 2025.

    How fast is X4 Pharmaceuticals' revenue growing?

    Revenue was up 1273.2% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is X4 Pharmaceuticals profitable?

    No. X4 Pharmaceuticals reported net income of -$79.20M for the fiscal year ended Dec 31, 2025, with a net margin of -225.6%.

    How much free cash flow does XFOR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$85.62M minus capital expenditures of $0 produced free cash flow of -$85.62M.

    How much debt does X4 Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $76.29M, short-term debt of $994.00K and cash and equivalents of $217.05M.